DrugPatentWatch Database Preview
Drugs in Development Information for Momelotinib
Drug Development Status for Momelotinib: Sponsors, patents, clinical trial progress
Momelotinib is an investigational drug.
There have been 13 clinical trials for Momelotinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Thrombocytosis, Thrombocythemia, Essential, and Primary Myelofibrosis. The leading clinical trial sponsors are Gilead Sciences, Fred Hutchinson Cancer Research Center, and National Heart, Lung, and Blood Institute (NHLBI).
There are twenty-seven US patents protecting this investigational drug and three hundred international patents.
Summary for Momelotinib
| US Patents | 27 |
| International Patents | 300 |
| US Patent Applications | 54 |
| WIPO Patent Applications | 42 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2014-06-01) |
| Vendors | 83 |
Recent Clinical Trials for Momelotinib
| Title | Sponsor | Phase |
|---|---|---|
| Extended Access of Momelotinib in Adults With Myelofibrosis | Gilead Sciences | Phase 2 |
| Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Gilead Sciences | Phase 2 |
| Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | Gilead Sciences | Phase 1 |
Clinical Trial Summary for Momelotinib
Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib
US Patents for Momelotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Momelotinib | Start Trial | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| Momelotinib | Start Trial | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | Start Trial |
| Momelotinib | Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| Momelotinib | Start Trial | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Momelotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Momelotinib | Argentina | 096246 | 2033-05-09 | Start Trial |
| Momelotinib | Australia | 2014262622 | 2033-05-09 | Start Trial |
| Momelotinib | Brazil | 112015028017 | 2033-05-09 | Start Trial |
| Momelotinib | Canada | 2911408 | 2033-05-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
